{"favorite_id": 10232, "calc_type": "diagnostic_criteria", "dosing": false, "full_title_en": "Multiple Myeloma Response Criteria", "short_title_en": "Multiple Myeloma Response Criteria", "medium_description_en": "Predicts disease response in multiple myeloma, from the International Myeloma Working Group (IMWG).", "short_description_en": "Multiple myeloma response assessment.", "before_use": "", "instructions_en": "", "purpose_en": ["Diagnosis"], "disease_en": ["Multiple Myeloma"], "specialty_en": ["Radiation Oncology", "Internal Medicine", "Hospitalist Medicine", "Hematology and Oncology"], "chief_complaint_en": ["Extremity Pain", "Cancer"], "system_en": ["Oncologic", "Hematologic"], "search_abbreviation_en": ["Mm", "Multiple Myeloma Response Criteria (IMWG)", "multiple myeloma", "disease response", "multiple myeloma response assessment", "myeloma", "imwg"], "slug": "multiple-myeloma-response-criteria", "seo": {"meta_description_en": "The Multiple Myeloma Response Criteria (IMWG) predicts disease response in multiple myeloma.", "keywords_en": "Mm, Multiple Myeloma Response Criteria (IMWG), multiple myeloma, disease response, multiple myeloma response assessment, myeloma, imwg"}, "content": {"how_to_use": {"use_case_en": "<p>Do you use the&nbsp;Multiple Myeloma Response Criteria and want to contribute your expertise?&nbsp;<a href=\"https://www.mdcalc.com/join-us\" target=\"_blank\">Join</a>&nbsp;our contributor team!</p>", "pearls_pitfalls_en": "", "why_use_en": ""}, "next_steps": {"advice_en": "<p>Do you use the&nbsp;Multiple Myeloma Response Criteria and want to contribute your expertise?&nbsp;<a href=\"https://www.mdcalc.com/join-us\" target=\"_blank\">Join</a>&nbsp;our contributor team!</p>", "management_en": "", "critical_actions_en": ""}, "about": {"formula_en": "<p dir=\"ltr\">Selection of the appropriate criteria:</p>\n<div dir=\"ltr\">\n<table><colgroup><col width=\"302\" /><col width=\"146\" /></colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>Criteria</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Response category</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND &lt;5% plasma cells in bone marrow</p>\n</td>\n<td>\n<p dir=\"ltr\">Complete response (CR)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">CR as defined above plus normal FLC ratio (0.26-1.65) AND absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence</p>\n</td>\n<td>\n<p dir=\"ltr\">Stringent complete response (sCR)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Serum and urine M component detectable by immunofixation but not on electrophoresis OR &ge;90% reduction in serum M component plus urine M component &lt;100&thinsp;mg per 24&thinsp;hrs</p>\n</td>\n<td>\n<p dir=\"ltr\">Very good partial response (VGPR)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">&ge;50% reduction of serum M protein and reduction in 24 hr urinary M protein by &ge;90% or to &lt;200&thinsp;mg per 24&thinsp;hrs</p>\n<p dir=\"ltr\">If serum and urine M protein are unmeasurable, &ge;50% decrease in the difference between involved and uninvolved FLC levels is required in place of the M protein criteria</p>\n<p dir=\"ltr\">If serum and urine M protein are unmeasurable, and serum free light assay is also unmeasurable, &ge;50% reduction in bone marrow plasma cells is required in place of M protein, provided baseline percentage was &ge;30%</p>\n<p dir=\"ltr\">In addition to the above criteria, if present at baseline, &ge;50% reduction in the size of soft tissue plasmacytomas is also required</p>\n</td>\n<td>\n<p dir=\"ltr\">Partial response (PR)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Not meeting criteria for CR, VGPR, PR, or progressive disease</p>\n</td>\n<td>\n<p dir=\"ltr\">Stable disease (SD)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">25% increase from lowest response value in &ge;1 of the following:</p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Serum M component (absolute increase must be &ge;0.5&thinsp;g/100&thinsp;mL)</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Urine M component (absolute increase must be &ge;200&thinsp;mg per 24&thinsp;hrs)</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Only in patients without measurable serum and urine M protein levels: difference between involved and uninvolved FLC levels (absolute increase must be &gt;100&thinsp;mg/L)</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Bone marrow plasma cell percentage (absolute % must be &ge;10%)</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Development of hypercalcemia (<calculator id=\"31\">corrected serum calcium</calculator>&nbsp;must be &gt;11.5&thinsp;mg/dL) that can be attributed solely to the plasma cell proliferative disorder</p>\n</li>\n</ul>\n</td>\n<td>\n<p dir=\"ltr\">Progressive disease (PD)</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>", "more_info_en": "", "evidence_based_medicine_en": "", "references_list": {"Original/Primary Reference": [{"href": "https://www.nature.com/articles/leu2008291/", "text": "Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3-9."}], "Other References": [], "Validation": [], "Clinical Practice Guidelines": [], "Manufacturer Website": [], "Outcomes": []}}, "contributor": {"expert_name": []}, "creator": [{"name": "Dr. Robert A. Kyle", "qa_en": "", "creator_info": {"about_en": "<p>Robert A. Kyle, MD, is a professor of medicine and laboratory medicine and pathology at the Mayo Clinic in Rochester, Minnesota. He is widely regarded as a pioneer in multiple myeloma research, having published numerous critical papers on topics including monoclonal gammopathies, multiple myeloma, amyloidosis, and macroglobulinemia.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-robert-a-kyle.jpg", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=kyle+ra%5Bau%5D"}}], "reviewer": {"expert_name": []}, "related_resources": {"mdcalc_rating": [], "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "toggle", "label_en": "Negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND <5% plasma cells in bone marrow", "default": 0, "conditionality": "", "show_points": false, "tips_en": "", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "one"}, {"type": "toggle", "label_en": "Criteria above plus normal <abbr title = \"Free light chain\">FLC</abbr> ratio (0.26-1.65) AND absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence", "default": 0, "conditionality": "", "show_points": false, "tips_en": "", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "two"}, {"type": "toggle", "label_en": "Serum and urine M component detectable by immunofixation but not on electrophoresis OR \u226590% reduction in serum M component plus urine M component <100\u2009mg per 24\u2009hrs", "default": 0, "conditionality": "one != 1", "show_points": false, "tips_en": "", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "three"}, {"type": "toggle", "label_en": "\u226550% reduction of serum M protein and reduction in 24 hr urinary M protein by \u226590% or to <200\u2009mg per 24\u2009hrs; if present at baseline, \u226550% reduction in the size of soft tissue plasmacytomas is also required", "default": 0, "conditionality": "one != 1", "show_points": false, "tips_en": "See <a href = \"#evidence\">Evidence</a> for criteria if serum and urine M protein are unmeasurable", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "four"}, {"subheading": "25% increase from lowest response value in the following (select any that apply):", "subheading_instructions": "", "type": "subheading"}, {"type": "toggle", "label_en": "Serum M component", "default": 0, "conditionality": "one != 1", "show_points": false, "tips_en": "Absolute increase must be \u22650.5\u2009g/100\u2009mL", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "five"}, {"type": "toggle", "label_en": "Urine M component", "default": 0, "conditionality": "one != 1", "show_points": false, "tips_en": "Absolute increase must be \u2265200\u2009mg per 24\u2009hrs", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "six"}, {"type": "toggle", "label_en": "Only in patients without measurable serum and urine M protein levels: difference between involved and uninvolved FLC levels", "default": 0, "conditionality": "one != 1", "show_points": false, "tips_en": "Absolute increase must be >100\u2009mg/L", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "seven"}, {"type": "toggle", "label_en": "Bone marrow plasma cell percentage", "default": 0, "conditionality": "one != 1", "show_points": false, "tips_en": "Absolute % must be \u226510%", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "eight"}, {"type": "toggle", "label_en": "Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas", "default": 0, "conditionality": "one != 1", "show_points": false, "tips_en": "", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "nine"}, {"type": "toggle", "label_en": "Development of hypercalcemia that can be attributed solely to the plasma cell proliferative disorder", "default": 0, "conditionality": "one != 1", "show_points": false, "tips_en": "<calculator id = \"31\">Corrected serum calcium</calculator> must be >11.5\u2009mg/dL", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "ten"}], "md5": "", "related_calcs": [{"calcId": 10233, "short_title_en": "Multiple Myeloma Diagnostic Criteria", "slug": "multiple-myeloma-diagnostic-criteria"}, {"calcId": 3929, "short_title_en": "Asymptomatic Myeloma Prognosis", "slug": "asymptomatic-myeloma-prognosis"}, {"calcId": 3842, "short_title_en": "Revised Myeloma ISS", "slug": "revised-multiple-myeloma-international-staging-system-r-iss"}]}